Immuneering to Participate in Upcoming Investor Conferences
Immuneering (IMRX) will participate in two New York investor conferences in September 2026, featuring fireside chats and 1x1 investor meetings.
Rhea-AI Summary
Immuneering (IMRX) will participate in two New York investor conferences in September 2026, featuring fireside chats and 1x1 investor meetings.
Management will appear at the Cantor Global Healthcare Conference on Thursday, September 10, 2026, from 2:45–3:15 pm ET, and at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, from 5:00–5:30 pm ET. Both fireside chats will be webcast live and later archived in the Investor Relations section of Immuneering’s website.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences:
Cantor Global Healthcare Conference (September 9-11 in New York City)
- Format: Fireside Chat and 1x1 Investor Meetings
- Date/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET
H.C. Wainwright 28th Annual Global Investment Conference (September 14-16 in New York City)
- Format: Fireside Chat and 1x1 Investor Meetings
- Date/Time: Monday, September 14, 2026, from 5:00-5:30 pm ET
The fireside chats will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.
Investor Contact:
Laurence Watts
New Street Investor Relations
laurence@newstreetir.com
Media Contact:
David Caouette
dcaouette@immuneering.com
FAQ
When will Immuneering (IMRX) present at the Cantor Global Healthcare Conference?
Immuneering will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10, 2026, from 2:45–3:15 pm ET in New York City, alongside 1x1 investor meetings.
What is the schedule for Immuneering (IMRX) at the H.C. Wainwright 28th Annual Global Investment Conference?
Immuneering is scheduled for a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, from 5:00–5:30 pm ET, with additional 1x1 investor meetings.
How can investors access the Immuneering (IMRX) conference webcasts in September 2026?
The fireside chats at both the Cantor Global Healthcare Conference and the H.C. Wainwright Global Investment Conference will be webcast live and later archived in the Investor Relations section of Immuneering’s website under Events & Presentations.
Where are the September 2026 investor conferences featuring Immuneering (IMRX) being held?
Both the Cantor Global Healthcare Conference (September 9–11) and the H.C. Wainwright 28th Annual Global Investment Conference (September 14–16), where Immuneering will participate, are being held in New York City.